690 related articles for article (PubMed ID: 33805800)
21. Targeting the cell division cycle in cancer: CDK and cell cycle checkpoint kinase inhibitors.
Collins I; Garrett MD
Curr Opin Pharmacol; 2005 Aug; 5(4):366-73. PubMed ID: 15964238
[TBL] [Abstract][Full Text] [Related]
22. An insight into the emerging role of cyclin-dependent kinase inhibitors as potential therapeutic agents for the treatment of advanced cancers.
Chohan TA; Qayyum A; Rehman K; Tariq M; Akash MSH
Biomed Pharmacother; 2018 Nov; 107():1326-1341. PubMed ID: 30257348
[TBL] [Abstract][Full Text] [Related]
23. Promises and drawbacks of targeting cell cycle kinases in cancer.
Pentimalli F; Giordano A
Discov Med; 2009 Dec; 8(43):177-80. PubMed ID: 20040266
[TBL] [Abstract][Full Text] [Related]
24. Cell cycle control as a basis for cancer drug development (Review).
McDonald ER; El-Deiry WS
Int J Oncol; 2000 May; 16(5):871-86. PubMed ID: 10762622
[TBL] [Abstract][Full Text] [Related]
25. The cyclin family of budding yeast: abundant use of a good idea.
Andrews B; Measday V
Trends Genet; 1998 Feb; 14(2):66-72. PubMed ID: 9520600
[TBL] [Abstract][Full Text] [Related]
26. Cyclin-dependent kinases in neural development and degeneration.
Lim AC; Qi RZ
J Alzheimers Dis; 2003 Aug; 5(4):329-35. PubMed ID: 14624029
[TBL] [Abstract][Full Text] [Related]
27. The Roles of Cyclin-Dependent Kinases in Cell-Cycle Progression and Therapeutic Strategies in Human Breast Cancer.
Ding L; Cao J; Lin W; Chen H; Xiong X; Ao H; Yu M; Lin J; Cui Q
Int J Mol Sci; 2020 Mar; 21(6):. PubMed ID: 32183020
[TBL] [Abstract][Full Text] [Related]
28. The Emerging Role of Cyclin-Dependent Kinases (CDKs) in Pancreatic Ductal Adenocarcinoma.
García-Reyes B; Kretz AL; Ruff JP; von Karstedt S; Hillenbrand A; Knippschild U; Henne-Bruns D; Lemke J
Int J Mol Sci; 2018 Oct; 19(10):. PubMed ID: 30340359
[TBL] [Abstract][Full Text] [Related]
29. Regulation of the Pcl7-Pho85 cyclin-cdk complex by Pho81.
Lee M; O'Regan S; Moreau JL; Johnson AL; Johnston LH; Goding CR
Mol Microbiol; 2000 Oct; 38(2):411-22. PubMed ID: 11069666
[TBL] [Abstract][Full Text] [Related]
30. The Pho85 kinase, a member of the yeast cyclin-dependent kinase (Cdk) family, has a regulation mechanism different from Cdks functioning throughout the cell cycle.
Nishizawa M; Suzuki K; Fujino M; Oguchi T; Toh-e A
Genes Cells; 1999 Nov; 4(11):627-42. PubMed ID: 10620010
[TBL] [Abstract][Full Text] [Related]
31. Cyclin dependent kinases in cancer: potential for therapeutic intervention.
Canavese M; Santo L; Raje N
Cancer Biol Ther; 2012 May; 13(7):451-7. PubMed ID: 22361734
[TBL] [Abstract][Full Text] [Related]
32. ATP-noncompetitive CDK inhibitors for cancer therapy: an overview.
Abate AA; Pentimalli F; Esposito L; Giordano A
Expert Opin Investig Drugs; 2013 Jul; 22(7):895-906. PubMed ID: 23735075
[TBL] [Abstract][Full Text] [Related]
33. The history and future of targeting cyclin-dependent kinases in cancer therapy.
Asghar U; Witkiewicz AK; Turner NC; Knudsen ES
Nat Rev Drug Discov; 2015 Feb; 14(2):130-46. PubMed ID: 25633797
[TBL] [Abstract][Full Text] [Related]
34. Dissecting the Pol II transcription cycle and derailing cancer with CDK inhibitors.
Parua PK; Fisher RP
Nat Chem Biol; 2020 Jul; 16(7):716-724. PubMed ID: 32572259
[TBL] [Abstract][Full Text] [Related]
35. Investigational drugs targeting cyclin-dependent kinases for the treatment of cancer: an update on recent findings (2013-2016).
Di Giovanni C; Novellino E; Chilin A; Lavecchia A; Marzaro G
Expert Opin Investig Drugs; 2016 Oct; 25(10):1215-30. PubMed ID: 27606939
[TBL] [Abstract][Full Text] [Related]
36. Cyclin-dependent kinase inhibitors for the treatment of chronic lymphocytic leukemia.
Blachly JS; Byrd JC; Grever M
Semin Oncol; 2016 Apr; 43(2):265-73. PubMed ID: 27040705
[TBL] [Abstract][Full Text] [Related]
37. Interaction of yeast Rvs167 and Pho85 cyclin-dependent kinase complexes may link the cell cycle to the actin cytoskeleton.
Lee J; Colwill K; Aneliunas V; Tennyson C; Moore L; Ho Y; Andrews B
Curr Biol; 1998 Dec; 8(24):1310-21. PubMed ID: 9843683
[TBL] [Abstract][Full Text] [Related]
38. Genetic alterations of cyclins, cyclin-dependent kinases, and Cdk inhibitors in human cancer.
Hall M; Peters G
Adv Cancer Res; 1996; 68():67-108. PubMed ID: 8712071
[No Abstract] [Full Text] [Related]
39. Cancer therapy: targeting cell cycle regulators.
Johansson M; Persson JL
Anticancer Agents Med Chem; 2008 Oct; 8(7):723-31. PubMed ID: 18855574
[TBL] [Abstract][Full Text] [Related]
40. The roles and therapeutic potential of cyclin-dependent kinases (CDKs) in sarcoma.
Liao Y; Feng Y; Shen J; Hornicek FJ; Duan Z
Cancer Metastasis Rev; 2016 Jun; 35(2):151-63. PubMed ID: 26669603
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
